{
    "title": "ATACH-2 Trial",
    "link": "https://www.thebottomline.org.uk/summaries/icm/atach-2/",
    "summary": "In patients with acute intracerebral haemorrhage and who are hypertensive, does rapid lowering of systolic blood pressure compared to standard therapy improve patient outcomes ?",
    "full_content": "\nTweet\n\nIntensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage\nQureshi\u00a0et al. NEJM 2016 DOI: 10.1056/NEJMoa1603460\nClinical Question\n\nIn patients with acute intracerebral haemorrhage and who are hypertensive, does rapid lowering of systolic blood pressure compared to standard therapy improve patient outcomes ?\n\nDesign\n\nRandomised, multi-centre, open-label\nCentral randomisation using trial website by minimisation algorithm combined with biased-coin method\nFollow up period of 3 months\nPower calculation based on assumption that death or disability would be 10% lower in intervention group. Expected control event rate of 60%.\n\nalpha error 0.05, power 90%\nSample size of 1280 required taking into account non-adherence\n\n\nIntention-to-treat analysis\n\nSetting\n\n110 sites in United States, Japan, China, Taiwan, South Korea and Germany\nMay 2011 to September 2015\n\nPopulation\n\nInclusion:\n\n18 years and above\nGCS > 4\nIntraparenchymal haematoma of less than 60cm3 on initial CT scan\nWithin 3 hours (extended to 4.5 hours) of symptom onset\n\nAt least one\u00a0reading of systolic blood pressure of 180 mmHg\u00a0or more between symptom onset and the initiation\u00a0of intravenous antihypertensive treatment\n\n\n\nExclusion:\n\nTime of symptom onset not reliably established\nPreviously known AVM, neoplasm or aneurysm\nIntracerebral hematoma considered to be related to trauma.\nlCH located in infratentorial regions such as pons or cerebellum\nIVH associated with intraparenchymal hemorrhage and blood completely fills one lateral ventricle or more than half of both ventricles\nSubject is considered a candidate for immediate surgical intervention by the neurosurgery service\nPregnancy or parturition within previous 30 days or active lactation\nAny history of bleeding diathesis or coagulopathy\nUse of warfarin within the last 5 days\nA platelet count less than 50,000/mm3\nKnown sensitivity to nicardipine\nPre-morbid mRS of 4 or greater\nSubject\u2019s living will precludes aggressive ICU management\n\n\n8532 patients screened, 1000 randomised\n\nIntervention\n\n*\u00a0Treatment could be\u00a0initiated before randomisation to lower the systolic\u00a0blood pressure to less than 180 mmHg but were excluded if systolic BP reduced below 140 mmHg before randomisation\n\nTarget systolic BP 110 to 139 mmHg throughout the 24 hours after randomisation\n\n\nControl\n\nTarget systolic BP\u00a0140 to 179 mmHg throughout the 24 hours after randomisation\n\nManagement common to both groups\n\n1st line = IV nicardipine infusion\n\ninitiated at 5mg/hr, increased by 2.5mg/hour every 15 minutes as needed, up to a maximum dose of 15mg/hr\n\n\n2nd line (if target not achieved after 30 mins) = IV labetalol (IV diltiazem or urapidil if labetolol not available)\n\nOutcome\n\nPrimary outcome:\n\nProportion of patients who had modified Rankin scores 4 to 6 at 3 months (significant disability or death)\n\nNo difference between groups (38.7% in intervention, 37.7% in control)\n\nUnadjusted analysis: relative risk 1.02 (CI 0.83 \u2013 1.25, p=0.84)\nAdjusted analysis: relative risk 1.04 (CI 0.85 \u2013 1.27, p=0.72)\n\n\n\n\n\n\nSecondary outcome:\n\nUnadjusted analysis showed no difference between groups in:\n\nEQ-5D scores at 3 months\nVAS at 3 months\nProportion of patients with expansion of 33% or more in volume of haematoma on 24 hour scan compared to baseline scan\nSafety outcomes (fall in GCS by 2 or increase of NIH Stroke Score by 4)\nIncidence of serious adverse events within 72 hours\n\n\nHigher incidence of serious adverse events within 3 months in intervention group when analysis adjusted\n\n25.6% in intervention, 20% in control; p=0.05\n\n\n\n\n\n\u00a0\n\nPrimary treatment failure = not achieving target within 2 hours after randomisation\n\n61 (12.2%) in intervention arm, 4 (0.8%) in control arm; p<0.001\n\n\nSecondary treatment failure = hourly minimum systolic BP above target range for 2 consecutive hours during the period of 2 to 24 hours after randomisation\n\n78 (15.6%) in intervention arm, 7 (1.4%) in control arm; p<0.001\n\n\n\nAuthors\u2019 Conclusions\n\nThe results of the trial do not support the reduction of systolic blood pressure to a target of 110 to 139 mmHg in patients with intracerebral haemorrhage\n\nStrengths\n\nMulti-centre trial\nClinically meaningful and relevant outcome measures\n\nWeaknesses\n\nRecruitment criteria changed during the trial\nReasons for failure to randomise screened population not included\nUnder-powered \u2013 power calculations based on event rate of 60%, actual observed event rate in study of 38%, increasing likelihood ot type 2 error\nMore than 50% of patients recruited from Asia sites and may not be reflective of European population\nIntracerebral haemorrhage grouped\u00a0as a single entity\nSignificant difference between groups with regards to treatment failure (primary and secondary)\n\nThe Bottom Line\n\nThe results of this trial and that of the INTERACT2 trial do not support an early, intensive control of systolic blood pressure in patients with acute intracranial haemorrhage\n\nExternal Links\n\n[article]\u00a0Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage\n[further reading]\u00a0Supplementary material\n[further reading]\u00a0Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage (INTERACT2)\n\nMetadata\nSummary author:\u00a0Adrian Wong\nSummary date: 15 July 2016\nPeer-review editor: Duncan Chambler\n\n\n"
}